Search This Blog

Monday, October 5, 2026

Mizuho initiated coverage of Regenxbio with an Outperform rating and $22 price target

 highlighting RGX-202 and Sura-Vec as key upside drivers

https://finviz.com/stock?t=RGNX&p=d

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)